Pulsed Radiofrequency
Customize your policy alerts
Sign up for Aetna Policy 0735 alerts
Get alerted when Policy 0735 changes without checking for updates manually.
Monitor payer policy activity
This clinical policy bulletin addresses the coverage stance and coding guidance for pulsed radiofrequency procedures and related modalities for Aetna members.
No material clinical or coverage changes in this revision.
Coverage Criteria — Pulsed Radiofrequency
inv-01: Experimental and Investigational — Aetna considers pulsed radiofrequency experimental and investigational for all indications, including the enumerated list
Aetna considers pulsed radiofrequency experimental and investigational for all indications listed below because effectiveness has not been established.
See source for full enumerated list
inv-02: Modalities - Experimental/Investigational — specific PRF modalities considered unestablished
The following specific PRF modalities are considered experimental and investigational because effectiveness has not been established.
inv-03: Covered with conditions — selective indications supported by limited evidence
Selected scenarios in the literature where limited evidence suggests PRF may provide benefit in carefully selected patients:
Careful patient selection and further research recommended.
Diagnostic nerve block was an inclusion criterion in reported studies.
Results variable; randomized trials needed.
Placebo‑controlled RCTs are generally lacking for these indications.
inv-04: Not supported / inferior evidence — scenarios where PRF is not supported or inferior
Scenarios in which available trials do not support PRF or show inferiority to alternative treatments:
PRF not supported as effective for trigeminal neuralgia in available RCT evidence.
Evidence level rated poor.
inv-05: Overall coverage summary — summary stance based on presented evidence
Overall coverage stance based on the body of evidence summarized in this document:
Based on multiple systematic reviews and summaries noting limited or poor evidence.
inv-06: Conditional positive findings — selected condition-level findings
Selected condition‑level findings from small RCTs or series that suggest potential benefit but are not definitive coverage criteria:
Promising but not definitive.
Preliminary positive outcomes reported.
Promising but limited evidence.
inv-07: Evidence considerations — evidence summary and implications for coverage determination
Key evidence considerations and implications for coverage determinations:
Decisions should weigh study quality, comparator treatments, and reproducibility.
inv-08: Evidence summaries by indication — evidence and conclusions for specific indications
Evidence and conclusions reported in the document for specific indications (summarized):
Authors call for larger RCTs.
Small uncontrolled data.
Short follow‑up limits conclusions.
Promising single‑center data.
Larger RCTs needed.
Preliminary evidence.
Preliminary findings.
Further confirmation desirable.
Not translatable without human studies.
Low‑quality evidence.
High‑quality negative trial for this indication.
inv-09: Coverage-relevant evidence summaries — limited, heterogeneous studies summarized
Summarized, coverage‑relevant evidence across multiple reviews and trials (limited and heterogeneous):
Akural et al. RCT: inclusion pain ≥5 NRS and ≥6 months duration; prior temporary block required.
Hetta et al. RCT: validation needed.
Requires randomized evaluation.
Larger RCTs needed.
Vuka et al. reviews and others summarize small heterogeneous studies.
inv-10: Coverage-relevant clinical criteria (evidence-informed) — clinical use considerations drawn from evidence
Evidence‑informed clinical considerations (not formal coverage criteria) that reflect the document’s conclusions:
Examples include refractory shoulder pain, zoster‑related pain, trigeminal PHN, lumbar radicular pain, chronic hip pain; use supported by case series/RCTs is variable.
stSCS superiority noted in meta‑analysis for zoster‑related pain.
Single‑center RCT showed PRF+DEX superior to PRF alone for trigeminal PHN.
Aetna considers pulsed radiofrequency (PRF) experimental and investigational for the enumerated indications because effectiveness has not been established. The policy lists 71 specific indications for which PRF is considered investigational, including but not limited to cervical radicular pain, occipital neuralgia, sacro‑iliac joint pain, peripheral post‑traumatic neuropathic pain, trigeminal neuralgia, post‑herpetic neuralgia, plantar fasciitis, and zoster‑related pain.
PRF neurotomy/denervation procedures have been judged to have poor or limited evidence in some reviews of spinal injection therapies; moreover, certain external payer programs may not recognize PRF neurotomy as an established component of covered spinal injection services. Where local payer rules differ, PRF neurotomy may be excluded or denied based on those external program determinations.
The document concludes there is insufficient evidence to support routine use of PRF for a variety of chronic pain syndromes. Across thoracic pain and other chronic pain conditions the literature is small, heterogeneous, and often limited to retrospective series; well‑designed randomized controlled trials with longer follow‑up are generally lacking.
Although the Stimpod NMS460 received FDA clearance for symptomatic relief of chronic intractable pain, the policy notes insufficient evidence on the clinical value of this device in broader use. The bulletin does not provide explicit coverage‑exclusion language tied solely to device regulatory status, but it states that clinical effectiveness remains unestablished.
Data for palmar hyperhidrosis are limited to preclinical (animal) studies; no human clinical evidence demonstrating efficacy of PRF for this indication is provided, and translation to clinical practice is unsupported by human data.
A network meta‑analysis for plantar fasciitis found that ultrasound‑guided PRF (UG‑PRF) was not recommended and did not show stable, superior benefit compared with leading alternatives (for example, radial extracorporeal shock wave therapy). The review concluded UG‑PRF and high‑intensity focused shock wave were not endorsed as effective options in that analysis.
Post‑arthroplasty patients may present anatomic distortion that makes identification of the neurovascular bundle difficult. When the anatomic target cannot be clearly identified (for example after total knee arthroplasty), study authors cautioned that PRF outcomes may be unreliable and procedures were performed only when the bundle could be clearly visualized.
A systematic review and meta‑analysis of pulsed RF for chronic shoulder pain found no analgesic or functional benefit versus conventional medical management (GRADE: low). The lack of demonstrated benefit in shoulder pRF meta‑analysis suggests PRF should not be routinely expected to provide clinically meaningful improvement for shoulder indications without stronger supporting data.
Consistent with the evidence summaries, use of pulsed radiofrequency for the listed indications and the specified unestablished modalities is considered not medically necessary / investigational when offered outside well‑designed clinical research or carefully selected protocols because effectiveness has not been established.
For example, in the only prospective randomized double‑blind trial of PRF for idiopathic trigeminal neuralgia, PRF was found to be ineffective compared with continuous RF thermocoagulation; pain recurred by 3 months in the PRF group and investigators concluded PRF was ineffective for that indication.
PRF neurotomy has been compared to other treatments (for example conventional RF neurotomy or intra‑articular steroid injections) in reviews of sacro‑iliac and other joint interventions, where PRF evidence was judged poor. Given the limited and low‑quality evidence, PRF neurotomy should be considered investigational relative to established approaches such as cooled RF neurotomy or other therapies with stronger evidence.
Systematic reviews of cervicogenic and cluster headache interventions report very limited benefit from PRF approaches and note absence of high‑quality RCTs. Small case series and prospective cohorts have reported symptomatic improvements, but reviewers emphasize the need for larger, methodologically rigorous trials before routine use can be supported.
Coding and Diagnosis Mapping
| H93.11 | Tinnitus, subjective, right ear |
| H93.12 | Tinnitus, subjective, left ear |
| H93.13 | Tinnitus, subjective, bilateral |
| H93.14 | Tinnitus, subjective, unspecified ear |
| H93.15 | Tinnitus, objective, right ear |
| H93.16 | Tinnitus, objective, left ear |
| H93.17 | Tinnitus, objective, bilateral |
| H93.18 | Tinnitus, objective, unspecified ear |
| H93.19 | Tinnitus, other |
| B02.21 | Zoster with other nervous system involvement |
| There are no specific CPT codes for pulsed radiofrequency; report using related radiofrequency/nerve destruction codes as clinically appropriate and per payer guidance. |
Provider Actions — Prior Authorization, Documentation, and Denial Risk
Prior authorization recommended for transcutaneous PRF (TCPRF)
Controlled trials exist for transcutaneous PRF (TCPRF) in limited indications; when TCPRF or other limited‑evidence PRF modalities are requested, prior authorization is recommended so documented trial protocols and indication justification can be reviewed.
Prior authorization may be required due to insufficient evidence
Because the evidence is insufficient for many PRF indications, prior authorization may be required when PRF is requested; documentation should demonstrate the clinical rationale and prior conservative care.
Provide prior diagnostic block and conservative therapy documentation
Submit documentation of prior diagnostic block response and trials of conservative therapy (medications, physical therapy, prior injections) and baseline pain/quality‑of‑life measures when requesting PRF for headache/cervicogenic or chronic pain indications.
- Record degree of relief from diagnostic block (e.g., ≥50% relief where reported).
- Provide pre‑procedure VAS/NRS and validated QOL scores and prior treatment history.
Prior authorization scrutiny for peripheral post‑traumatic neuropathic pain
For peripheral post‑traumatic neuropathic pain, a randomized, double‑blind, sham‑controlled trial found no benefit of PRF over sham; requests for PRF in this indication should face heightened prior authorization scrutiny.
Prior authorization recommended for PRF because evidence quality is low
Given low and variable quality of evidence across neuropathic and non‑neuropathic indications, prior authorization is appropriate when PRF is requested to ensure documentation of prior conservative therapies and rationale for the procedure.
Include evidence summary (RCTs/meta‑analyses) to justify prior authorization
Cite randomized trials, systematic reviews, or meta‑analyses showing short‑term pain reductions and variable functional outcomes when justifying PRF in prior authorization requests.
- Document relevant RCTs or meta-analyses and their reported outcomes (pain, function, follow‑up intervals).
Prior authorization for indications with limited or mixed evidence
Consider prior authorization for PRF requests for indications with limited or mixed evidence (for example chronic shoulder pain, zoster‑related pain, trigeminal PHN) to ensure appropriate selection and alternative therapies were considered.
- Highlight comparative evidence (e.g., stSCS vs PRF for zoster‑related pain) where relevant.
No plan‑level prior authorization codes listed — check plan resources
The bulletin does not list specific CPT/HCPCS codes that require prior authorization for PRF; providers should follow plan‑specific prior authorization resources and code lists.
Studies often required prior failure of conservative measures before PRF
Some cited studies required prior failure of conservative measures (diagnostic SIJ injections, physical therapy, repeat injections, analgesics) before PRF; prior authorization may require evidence of such trials.
Document conservative therapies and diagnostic blocks before PRF
Document prior conservative treatments (medications, injections, physical therapy) and diagnostic block results before PRF; studies frequently enrolled patients refractory to conventional therapy.
- Indicate duration and outcomes of prior therapies and positive/temporary responses to diagnostic blocks.
Expect conservative treatments before considering PRF
Conservative treatments such as medications, injections, and physical therapy are generally expected prior to PRF given limited supporting evidence; include this history in authorization requests.
Document failure of meds, PT, and prognostic blocks before PRF
Evidence descriptions emphasize prior failure of medications, physical therapy, and prognostic blocks before PRF is used for conditions like coccydynia and meralgia paresthetica; document these failures.
Try PVN PRF before thoracic DRG PRF; document step‑up approach
For post‑mastectomy intercostobrachial neuralgia, trial data suggest attempting thoracic PVN PRF before thoracic DRG PRF because DRG targeting carries greater technical risk; document PVN failure before DRG PRF requests.
- If DRG PRF is requested, include documentation that PVN PRF was attempted and failed or was not feasible.
Document stepwise conservative management before PRF
Many studies used PRF after failure of other treatments; prior authorization should require documentation of stepwise conservative management before approving PRF.
Require prior conservative therapy and diagnostic medial branch block documentation
Mid‑cervical medial branch PRF in studies was performed after failure of conservative care and positive diagnostic medial branch blocks; include prior block results and conservative care details in the record.
Implied stepwise escalation: document prior therapies and surgical history
PRF is commonly used after failure of conservative therapies and occasionally after surgery; prior authorization should verify prior noninvasive and more conservative interventions have been attempted.
Provide supporting documentation of indication and prior conservative care
Clinical documentation should support the indication and prior conservative therapies; many studies used diagnostic blocks and prior injections as selection criteria for PRF.
- Include prior diagnostic block details, prior injections, and duration/outcomes of conservative therapy.
Document positive diagnostic block response for occipital neuralgia
Document a positive diagnostic nerve block response prior to PRF for occipital neuralgia when applicable, as used in prospective studies selecting patients for treatment.
- Specify block agent, volume, and measured percent relief and duration.
Include target, guidance method, and PRF parameters in procedure report
Procedural reports should include the anatomic target, image‑guidance modality (fluoroscopy, CT, or ultrasound), and PRF parameters (voltage, temperature, pulse width, duration) when available.
- Record guidance method and any sensory/motor stimulation thresholds used.
- Include PRF settings (e.g., 42°C for 120 seconds where reported) and number of applications.
Record prior block response and baseline/follow‑up pain and QOL measures
Required clinical documentation for PRF requests includes prior diagnostic block response, pre‑ and post‑procedure pain and QOL measures, and follow‑up outcomes to support effectiveness claims.
- Pre‑procedure VAS/NRS and validated QOL scores (e.g., SF‑36, SPADI) and post‑procedure follow‑up values.
- Degree of relief from diagnostic blocks (percent) and duration of symptoms.
Use and document baseline/follow‑up scores and responder definitions (≥30% or ≥50%)
Document baseline and follow‑up pain scores and use common responder definitions (studies commonly used ≥30% or ≥50% pain reduction) when reporting outcomes after PRF.
- State responder threshold applied (e.g., ≥50% reduction in VAS) and time‑points of measurement.
Include indication, prior therapies, and diagnostic block responses in documentation
Include indication, prior conservative treatments, and diagnostic block responses in the prior authorization package; studies routinely required these elements for patient selection.
Document trial endpoints (VAS, SPADI, SF‑36) and adverse events
Outcome measurement documentation from trials includes VAS, SPADI, SF‑36 and adverse events; include these measures at specified time‑points when available to support clinical benefit.
Recommended documentation: indication, prior measures, diagnostic blocks, and outcome scores
Clinical documentation supporting PRF requests should include the specific indication, prior conservative measures tried, diagnostic block details, and baseline and follow‑up outcome scores.
- List prior surgeries or interventions and their outcomes when relevant (e.g., prior TKA for genicular PRF).
Follow plan‑specific documentation and prior authorization processes
This policy bulletin is informational and partial; follow plan‑specific documentation and prior authorization processes because the bulletin does not specify all plan requirements.
Denial risk for indications listed as experimental/investigational
Procedures for indications listed as experimental and investigational are subject to denial because effectiveness has not been established for those indications.
Evidence quality concerns may trigger denial of coverage
High or medium risk of bias and generally poor study quality reported in reviews may lead payers to deny coverage when evidence of efficacy is insufficient for the specific indication.
Insufficient evidence may lead to noncoverage outside research settings
Insufficient evidence for many chronic pain syndromes means PRF offered outside well‑designed research protocols may be denied or considered noncovered.
No prior diagnostic block response increases risk of non‑response and denial
Lack of a prior diagnostic block response is associated with lower likelihood of PRF success (for example, C2 DRG PRF success was linked to prior ≥50% relief from a C2 DRG block); absence of such a response may increase denial risk.
Negative RCT for peripheral post‑traumatic neuropathic pain increases denial risk
A double‑blind, sham‑controlled RCT failed to show efficacy of PRF over sham for peripheral post‑traumatic neuropathic pain; that high‑quality negative trial may be used as a basis for denial in this indication.
Denial risk due to low‑quality or preliminary evidence
Because the overall evidence is low and preliminary for many PRF applications, payers may deny coverage when high‑quality randomized evidence is lacking or when PRF is used without comparative data.
Anatomic target identification issues may affect coverage
When anatomic targets cannot be clearly identified (for example post‑arthroplasty distortion of the neurovascular bundle), appropriateness of PRF is affected and this may lead to noncoverage.
Evidence limitations for shoulder PRF may prompt denials
Limited or negative evidence for shoulder PRF (meta‑analysis showing no analgesic or functional benefit) could prompt denials for shoulder indications absent stronger supporting documentation.
Policy bulletin is partial — verify member benefits and prior authorization rules
Clinical Policy Bulletins are informational and partial; coverage and denial decisions depend on plan terms, so providers must verify benefits and follow prior authorization processes.
Conservative Treatment Requirements Before PRF
inv-79: Prior conservative management or diagnostic injections commonly used in cited literature before PRF
Document prior conservative therapies and diagnostic/prognostic blocks as typically required by cited studies before PRF is considered:
Multiple studies and reviews selected patients refractory to conservative therapy; see cited literature.
Several prospective studies used diagnostic block response for patient selection.
Documented inadequate response commonly ≥6 months in some RCTs.
Many studies reported detailed procedural parameters and outcome measures.
inv-80: Document failure of conservative therapies and, where applicable, a positive diagnostic nerve block prior to PRF.
Document failure of conservative therapies and, when applicable, a positive diagnostic nerve block prior to PRF.
Case series and trials commonly enrolled patients refractory to previous management.
Prospective occipital PRF studies required a positive test block.
inv-81: Failure of appropriate conservative management (meds, PT, diagnostic blocks) expected before PRF is considered.
Failure of appropriate conservative management (medications, physical therapy, diagnostic blocks) is expected before PRF is considered.
Systematic reviews and series emphasize selection of refractory patients.
inv-82: Documentation of failed conservative treatments and/or positive diagnostic/prognostic block response is appropriate prior to PRF.
Documentation of failed conservative treatments and/or positive diagnostic/prognostic block response is appropriate prior to PRF.
Multiple reports describe PRF after failure of conservative therapies.
Positive block response was associated with better outcomes in some series.
inv-83: Documented inadequate response to conservative therapy and, when applicable, diagnostic nerve block prior to PRF (commonly ≥6 months in some RCTs).
Documented inadequate response to conservative therapy and, when applicable, diagnostic nerve block prior to PRF (trial durations in RCTs commonly ≥6 months).
Some RCTs required ≥6 months of symptoms prior to enrollment.
Positive prognostic block predicted better outcomes in some studies.
inv-84: Document prior conservative treatments and failed interventions prior to PRF; diagnostic blocks commonly used for selection.
Document prior conservative treatments and failed interventions prior to PRF; diagnostic blocks commonly used for selection.
Most studies enrolled patients after other therapies failed.
DRG‑targeted PRF studies typically initiated PRF after other treatments failed.
inv-85: Document prior conservative treatment attempts and prior diagnostic or therapeutic blocks when applicable.
Document prior conservative treatment attempts and prior diagnostic or therapeutic blocks when applicable.
Studies applied PRF after failure of conservative management and diagnostic blocks.
inv-86: Document prior conservative treatments and their failure before PRF for chronic refractory pain indications.
Document prior conservative treatments and their failure before PRF for chronic refractory pain indications.
Case reports and series commonly used PRF after other treatments failed.
Frequency Limits and Repeat Treatment
Imaging and Guidance for PRF Procedures
Fluoroscopy commonly used for PRF procedures
Fluoroscopy is commonly used for PRF procedures and is described in background as the typical imaging modality for needle placement.
Use CT/fluoroscopy/ultrasound as appropriate to the target and document it
PRF procedures targeting various nerves or joints have been performed with CT, fluoroscopy, or ultrasound as appropriate to the anatomic target; document the imaging modality used.
- Use the imaging modality appropriate to the target (CT for foramen ovale/Gasserian ganglion, US for peripheral nerves, fluoroscopy for spinal/DRG targets).
C2 DRG and similar procedures: fluoroscopy or ultrasound as clinically appropriate
For C2 DRG and other cervical procedures, fluoroscopy or ultrasound guidance is reported as clinically appropriate; include guidance modality in procedural documentation.
Image guidance commonly required for DRG, peripheral nerve, ganglion, and genicular PRF
Image guidance (fluoroscopy or ultrasound) is commonly necessary and should be used/documented when targeting DRG, peripheral nerves, ganglion impar, supraorbital nerve, or genicular nerves.
- Document target localization method (US or fluoroscopy) and any stimulation testing performed.
Definitions and Terminology
Not Covered / Exclusions (Documented Items)
All indications and listed modalities identified in the policy are considered not covered / investigational in routine practice. Providers requesting PRF for any of the enumerated conditions should be aware that those uses are deemed investigational and therefore subject to non‑coverage or denial unless presented as part of approved research or supported by strong, plan‑specific justification.
PRF for idiopathic trigeminal neuralgia is specifically referenced as not covered when RCT evidence demonstrates inferiority to continuous RF; the randomized trial cited showed PRF to be ineffective versus continuous RF thermocoagulation.
Routine use of PRF for many chronic pain syndromes is not supported by the available evidence. Systematic reviews and summary analyses repeatedly describe the evidence as poor, heterogeneous, or insufficient to establish clinical benefit, supporting a not‑covered stance for routine application.
The trial showing PRF inferior to continuous RF in trigeminal neuralgia is referenced multiple times in the evidence summaries and is an explicit example of an indication where PRF is not supported by randomized comparative data.
Duplicate placeholders referencing the trigeminal neuralgia trial reiterate that where RCT data demonstrate inferiority of PRF to established alternatives, PRF is considered not covered for that indication.
Additional duplicate placeholders emphasize the policy position that the enumerated investigational indications and specified modalities are not covered in routine practice.
Further duplicate entries reiterate that PRF uses listed in the policy are investigational and not covered absent compelling, plan‑specific evidence.
These repeated not‑covered placeholders reflect the policy's comprehensive enumeration of investigational PRF indications and modalities.
The policy's list of investigational indications and modalities is extensive; the repeated not‑covered placeholders flag multiple entries from that list as outside routine coverage.
Additional not‑covered placeholders correspond to individual items in the enumerated list and reiterate the investigational status across indications.
Background and Evidence Context
Radiofrequency procedures are minimally invasive interventions used for chronic pain management. Pulsed radiofrequency (PRF) is a non‑ablative variant that delivers short bursts of radiofrequency energy intended to neuromodulate neural structures while avoiding the tissue temperatures associated with continuous (ablative) RF. The evidence base for PRF is dominated by case series and small trials with limited long‑term follow‑up, and reported benefits are often short‑term and variable across indications.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.